Paul J Pagano

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Effects of linezolid on staphylococcal adherence versus time of treatment
    Paul J Pagano
    Pfizer Kalamazoo, MI 49007, USA
    Int J Antimicrob Agents 23:226-34. 2004
  2. doi request reprint Synthesis and structure-activity studies of novel homomorpholine oxazolidinone antibacterial agents
    Ji Young Kim
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Bioorg Med Chem Lett 19:550-3. 2009
  3. pmc Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis
    Charlene F Dailey
    Pharmacology, Pfizer, Kalamazoo, Michigan 49001, USA
    Antimicrob Agents Chemother 47:2655-8. 2003
  4. ncbi request reprint Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound
    Toni Jo Poel
    Michigan Laboratories, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Med Chem 50:5886-9. 2007

Collaborators

  • Michael D Huband
  • Allison L Choy
  • Frederick E Boyer
  • Ji Young Kim
  • Michael R Barbachyn
  • J V N Vara Prasad
  • Toni Jo Poel
  • Charlene F Dailey
  • Michael Dermyer
  • Richard C Thomas
  • Cai Hongliang
  • Joanne Brodfuehrer
  • Robert C Gadwood
  • Michael Dority
  • Christopher Huber
  • Daniel Ross
  • Debra Hanna
  • Laura Skerlos
  • Tong Zhu
  • Mark C Sulavik
  • Rose Kelly
  • Charles W Ford
  • Wade J Adams
  • Alan P Brown
  • Joan Brieland
  • Gary E Zurenko
  • Paul A Aristoff
  • J V N Vara Prasad
  • Roger Brideau
  • Joseph P Martin
  • John K Gibson
  • Joseph V Haas
  • Lewis V Buchanan
  • Jennifer A Paquette

Detail Information

Publications4

  1. ncbi request reprint Effects of linezolid on staphylococcal adherence versus time of treatment
    Paul J Pagano
    Pfizer Kalamazoo, MI 49007, USA
    Int J Antimicrob Agents 23:226-34. 2004
    ..Linezolid has promising in vitro anti-adhesion activity that merits further studies to determine its role in the management of foreign-body infections...
  2. doi request reprint Synthesis and structure-activity studies of novel homomorpholine oxazolidinone antibacterial agents
    Ji Young Kim
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Bioorg Med Chem Lett 19:550-3. 2009
    ..Various C-5 functional groups were also examined, including acetamides and triazoles and carboxamides...
  3. pmc Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis
    Charlene F Dailey
    Pharmacology, Pfizer, Kalamazoo, Michigan 49001, USA
    Antimicrob Agents Chemother 47:2655-8. 2003
    ..The results from this experimental model of endocarditis suggest that while rifampin did not provide synergy to the linezolid dosing, it did not antagonize the efficacy of linezolid...
  4. ncbi request reprint Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound
    Toni Jo Poel
    Michigan Laboratories, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Med Chem 50:5886-9. 2007
    ..The title compound (14) showed reduced in vivo myelotoxicity compared to linezolid in a 14-day safety study in rats, potent in vivo efficacy in murine systemic infection models, and excellent pharmacokinetic properties...